Bronchitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Bronchitis - Pipeline Review, H1 2016', provides an overview of the Bronchitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Bronchitis - The report reviews pipeline therapeutics for Bronchitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Bronchitis therapeutics and enlists all their major and minor projects - The report assesses Bronchitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Bronchitis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Bronchitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Bronchitis Overview 6 Therapeutics Development 7 Pipeline Products for Bronchitis - Overview 7 Bronchitis - Therapeutics under Development by Companies 8 Bronchitis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Bronchitis - Products under Development by Companies 12 Bronchitis - Companies Involved in Therapeutics Development 13 Boehringer Ingelheim GmbH 13 DBV Technologies S.A. 14 Hyundai Pharmaceutical Co., Ltd. 15 Invion Limited 16 Mucosis B.V. 17 Orbis Biosciences, Inc. 18 Recipharm AB 19 Bronchitis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 BI-113608 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 erdosteine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 HOB-051 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 nadolol - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 nitric oxide - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 prednisone - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 respiratory syncytial virus vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 SynGEM - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Bronchitis - Recent Pipeline Updates 41 Bronchitis - Dormant Projects 46 Bronchitis - Discontinued Products 48 Bronchitis - Product Development Milestones 49 Featured News & Press Releases 49 Oct 07, 2015: EVP R&D Dr Mitchell Glass discusses with BRR media data from the Phase 2 clinical trial of INV102 (nadolol) in Smoking Cessation 49 Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets 49 Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings 49 Jan 23, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants 50 Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 50 Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for Bronchitis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Bronchitis - Pipeline by Boehringer Ingelheim GmbH, H1 2016 13 Bronchitis - Pipeline by DBV Technologies S.A., H1 2016 14 Bronchitis - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 15 Bronchitis - Pipeline by Invion Limited, H1 2016 16 Bronchitis - Pipeline by Mucosis B.V., H1 2016 17 Bronchitis - Pipeline by Orbis Biosciences, Inc., H1 2016 18 Bronchitis - Pipeline by Recipharm AB, H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Bronchitis Therapeutics - Recent Pipeline Updates, H1 2016 41 Bronchitis - Dormant Projects, H1 2016 46 Bronchitis - Dormant Projects (Contd..1), H1 2016 47 Bronchitis - Discontinued Products, H1 2016 48
List of Figures
Number of Products under Development for Bronchitis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 10 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Targets, H1 2016 21 Number of Products by Stage and Targets, H1 2016 21 Number of Products by Mechanism of Actions, H1 2016 23 Number of Products by Stage and Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27 Number of Products by Stage and Molecule Types, H1 2016 27
Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. EvolvRead More...
Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the iRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving creamRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.